Aurisco Pharmaceutical Co Ltd
SSE:605116
Intrinsic Value
Aurisco Pharmaceutical Co., Ltd. engages in the development and production of pharmaceutical chemicals. [ Read More ]
The intrinsic value of one Aurisco Pharmaceutical Co Ltd stock under the Base Case scenario is 27.43 CNY. Compared to the current market price of 22.2 CNY, Aurisco Pharmaceutical Co Ltd is Undervalued by 19%.
Valuation Backtest
Aurisco Pharmaceutical Co Ltd
Run backtest to discover the historical profit from buying and selling Aurisco Pharmaceutical Co Ltd stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Aurisco Pharmaceutical Co Ltd
Current Assets | 1.3B |
Cash & Short-Term Investments | 521m |
Receivables | 269.5m |
Other Current Assets | 511.6m |
Non-Current Assets | 1.1B |
Long-Term Investments | 55.3m |
PP&E | 754.5m |
Intangibles | 120.6m |
Other Non-Current Assets | 134.1m |
Current Liabilities | 423m |
Accounts Payable | 124.6m |
Accrued Liabilities | 33.4m |
Short-Term Debt | 130.4m |
Other Current Liabilities | 134.5m |
Non-Current Liabilities | 74.9m |
Long-Term Debt | 38.3m |
Other Non-Current Liabilities | 36.6m |
Earnings Waterfall
Aurisco Pharmaceutical Co Ltd
Revenue
|
1.2B
CNY
|
Cost of Revenue
|
-519.3m
CNY
|
Gross Profit
|
642.3m
CNY
|
Operating Expenses
|
-383.7m
CNY
|
Operating Income
|
258.6m
CNY
|
Other Expenses
|
-1.6m
CNY
|
Net Income
|
257m
CNY
|
Free Cash Flow Analysis
Aurisco Pharmaceutical Co Ltd
What is Free Cash Flow?
Profitability Score
Profitability Due Diligence
Aurisco Pharmaceutical Co Ltd's profitability score is 62/100. The higher the profitability score, the more profitable the company is.
Score
Aurisco Pharmaceutical Co Ltd's profitability score is 62/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Aurisco Pharmaceutical Co Ltd's solvency score is 83/100. The higher the solvency score, the more solvent the company is.
Score
Aurisco Pharmaceutical Co Ltd's solvency score is 83/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Aurisco Pharmaceutical Co Ltd
According to Wall Street analysts, the average 1-year price target for Aurisco Pharmaceutical Co Ltd is 31.62 CNY with a low forecast of 31.31 CNY and a high forecast of 32.55 CNY.
Shareholder Return
Price
Aurisco Pharmaceutical Co Ltd
Average Annual Return | 30.79% |
Standard Deviation of Annual Returns | 20.06% |
Max Drawdown | -39% |
Market Capitalization | 8.9B CNY |
Shares Outstanding | 417 071 300 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Aurisco Pharmaceutical Co., Ltd. engages in the development and production of pharmaceutical chemicals. The company is headquartered in Taizhou, Zhejiang and currently employs 1,207 full-time employees. The company went IPO on 2020-09-21. The firm's main products are respiratory, cardiovascular, anti-infective and nervous system drugs, including flumethasone, fluticasone propionate, eplerenone, tenofovir, pregabalin and other APIs and intermediates. The firm distributes its products in domestic market and to overseas markets.
Contact
IPO
Employees
Officers
The intrinsic value of one Aurisco Pharmaceutical Co Ltd stock under the Base Case scenario is 27.43 CNY.
Compared to the current market price of 22.2 CNY, Aurisco Pharmaceutical Co Ltd is Undervalued by 19%.